Ds Healthcare Group Inc (DSKX) 1.83 $DSKX
DS Healthcare Group Files U.S. Patent on New Compound for Hair Loss
GlobeNewswire - Thu May 08, 7:00AM CDT
DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products, today announced it has filed its second patent with the U.S. Patent and Trademark Office. This new patent addresses the composition and methods of a new compound described as a calcium-activated potassium channel opening agent for topical treatment of hair loss. DS Healthcare had filed its first patent in October 2013 for its prescription hair loss product currently under development.
DS Healthcare Group to Roll Out Products in Sao Paulo the Largest City in Brazil's $46 Billion Beauty Market
GlobeNewswire - Thu Apr 10, 9:52AM CDT
DS Healthcare Group, Inc. (NASDAQ
SKX), a leading developer of personal care products, today announced it has signed a distribution agreement with Drogaria Iguatemi, the leading high-end retail drug store chain in Sao Paulo, Brazil. This marks the second major distribution agreement signed by DS Healthcare in Brazil's $43 billion beauty industry. The Company's products are experiencing robust sales growth in the Rio de Janeiro metropolitan area, as well as through DS Healthcare's Brazilian e-commerce site.
DS Healthcare Group Reports 2013 Year-End and Fourth Quarter Financial Results
GlobeNewswire - Fri Apr 04, 7:17AM CDT
DS Healthcare Group, Inc. (Nasdaq SKX), a leading developer of personal care products, today announced financial results for the three and twelve months ended December 31, 2013.
DS Healthcare Group to Open its First Retail Boutique as Part of Global Brand Strategy
GlobeNewswire - Thu Feb 27, 8:52AM CST
DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products, today announced it is in the process of opening its first DS Laboratories retail store scheduled to open in the third quarter of 2014. The store, to be located in the metro Miami area, will showcase DS Healthcare's line of products including its industry-leading Spectral line of hair loss treatments and Revita hair stimulating shampoo and conditioner. The move is part of the Company's broader strategy as it continues to build the premier global brand in clinically proven personal care products.
DS Healthcare Group Signs Agreement with Leading Global Healthcare Company
GlobeNewswire - Mon Feb 10, 7:02AM CST
DS Healthcare Group, Inc. (NASDAQ SKX), a leading developer of personal care products, today announced it has signed an agreement with a global healthcare company that ranks in the top 200 of the Fortune Global 500 list of largest corporations in the world in 2013. Per the terms of the agreement, DS Healthcare is providing the formulation, ingredients and its technology to the global healthcare company for use in a topical product. The product is to be launched and distributed by the global healthcare company under their own brand following successful development. Under the terms of the agreement, DS Healthcare will act as the exclusive ingredient supplier for a period of 5 years, which will automatically renew under certain conditions.
DS Healthcare Group Moves Prescription Hair Loss Treatment Forward with Appointment of Aptiv Solutions as CRO
GlobeNewswire - Mon Jan 27, 7:00AM CST
DS Healthcare Group, Inc. (NASDAQ SKX), a leading developer of personal care products, today announced it has appointed Aptiv Solutions as its clinical research organization (CRO) for its proprietary topical prescription treatment. If approved the drug will be positioned as frontline therapy in the fight against hair loss, a condition that affects nearly half of the population.
DS Healthcare Group Prepares to File Investigational New Drug Application with FDA for Prescription Hair Loss Treatment
GlobeNewswire - Thu Jan 09, 7:00AM CST
DS Healthcare Group, Inc.(NASDAQ SKX), a leading developer of personal care products, today announced it is preparing to submit to the United States Food and Drug Administration (FDA) an Investigational New Drug Application (IND) for its proprietary topical hair loss treatment. On October 29, 2013 the Company had announced it filed a patent with the United States Patent and Trademark Office for the invention. An IND is a request for the FDA's authorization to administer an investigational drug to humans and is the first step towards designing and conducting clinical trials in the U.S. DS Healthcare is currently in late stage discussions with various clinical research organizations (CROs) to design and conduct clinical trials for its breakthrough hair loss treatment.
DS Healthcare Group Inc concludes USD3.144m private placement
M2 - Tue Jan 07, 7:55AM CST
Personal care products company DS Healthcare Group Inc (Nasdaq SKX) announced on Monday the sale of 1,965,000 common shares for gross proceeds of USD3.144m to a group of accredited investors in a securities purchase agreement.
DS Healthcare Group Completes Private Placement of $3,144,000 Dollars
GlobeNewswire - Mon Jan 06, 7:01AM CST
DS Healthcare Group, Inc. (Nasdaq: DSKX), a developer of personal care products, today announced that it has completed its securities purchase agreement with a group of accredited investors for the sale of 1,965,000 shares of the Company's common stock, with gross proceeds of $3,144,000. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS) acted as the placement agent in connection with the offering.
DS Healthcare Group Announces Private Placement of $2,420,000 Million Dollars
GlobeNewswire - Wed Dec 25, 10:00AM CST
DS Healthcare Group, Inc. (Nasdaq: DSKX), a developer of personal care products, today announced that it entered and consummated a securities purchase agreement with an accredited investor for the sale of 1,512,500 shares of the Company's common stock, with gross proceeds of $2,420,0000. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), acted as the placement agent in connection with the offering.
DS Healthcare Group announces planned availibility of oral tablet in hair-loss market
M2 - Thu Dec 05, 7:04AM CST
Personal care products company DS Healthcare Group Inc (NasdaqCM SKX) stated on Wednesday that it will introduce its own proprietary over-the-counter neutraceutical tablet to combat premature hair thinning and improve healthy hair growth in the market.
DS Healthcare Group to launch oral tablet in multi-billion-dollar hair-loss market
GlobeNewswire - Wed Dec 04, 8:56AM CST
DS Healthcare Group Inc.(NASDAQ SKX), a leading developer of personal care products, announced that it has developed and will launch an over-the-counter neutraceutical tablet to combat premature hair thinning and improve healthy hair growth. Sold under the DS Laboratories brand, the tablet will complement and extend the company's industry-leading topical treatments, which promote longer, stronger, thicker hair.
DS Healthcare Group Reports Third Quarter 2013 Results
GlobeNewswire - Fri Nov 15, 9:30AM CST
DS Healthcare Group, Inc.(NASDAQ SKX), a leading developer of personal care products, today announced financial results for the three and nine months ended September 30, 2013.
DS Healthcare Group, Inc. to Present at the Aegis Capital Corporation 2013 Healthcare Conference
GlobeNewswire - Thu Sep 19, 11:30AM CDT
DS Healthcare Group, NASDAQ (DSKX) announced today that Daniel Khesin, DS Healthcare's CEO, will present at the at the Aegis Capital Corporation 2013 Healthcare Conference on Saturday, September 28, 2013 at 11:00 AM PDT. The conference will be held at the Encore at Wynn Las Vegas on September 26-28, 2013.
DS Healthcare Group Launches Brazilian E-Commerce Site to Support Sales Momentum in Fast Growing Beauty Market
GlobeNewswire - Wed Sep 11, 12:00PM CDT
DS Healthcare Group, Inc. (NASDAQ SKX), a leading developer of personal care products, today announced it has launched its Brazilian website: http://dslabshop.com.br. The e-commerce site provides convenient online shopping for Brazilians. The site also offers extensive product information to support in-stores sales of its products.
OTC Daily Alert Stock Watch - DS Healthcare Group, Inc., (NASDAQ: DSKX)
WorldStockWire - Fri Aug 30, 12:30AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
DS Healthcare Group Inc's net loss widens to USD757,063 in Q2 2013
M2 - Wed Aug 21, 10:40AM CDT
Personal care company DS Healthcare Group Inc (NasdaqCM SKX) stated on Tuesday its net loss of USD757,063 (USD0.06 per basic and diluted share) for the three months ended 30 June 2013.
DS Healthcare Group Reports Second Quarter 2013 Results
GlobeNewswire - Tue Aug 20, 5:00AM CDT
DS Healthcare Group, Inc. (NASDAQ SKX), a leading developer of personal care products, today announced results for the three and six months ended June 30, 2013.
DS Healthcare Group Expands its Distribution Channels in $43 Billion Brazilian Beauty Market
GlobeNewswire - Mon Aug 05, 9:30AM CDT
DS Healthcare Group, Inc. (NASDAQ SKX), a leading developer of personal care products, today announced it has expanded the distribution of its product lines into Brazil's CSB Drogaria which operates two retail pharmacy chains, Drogasmil and Farmalife, which together have 85 retail store locations. The stores are primarily located in the Rio de Janeiro metropolitan area. CSB Drogaria is owned by Profarma, a leader in the distribution to pharmacies, distributing 18 million units per month, through 31,000 sales outlets, covering 93% of the consumer market for pharmaceutical products in Brazil.
Healthcare Group Inc updates results from new clinical trial of Spectral.DNC-S in the treatment of thinning hair
M2 - Thu Jul 18, 6:26AM CDT
Biotechnology company DS Healthcare Group Inc (NasdaqCM SKX) Wednesday announced positive results from the clinical study of Spectral.DNC-S in the promotion of healthy hair and in the cessation of thinning hair in males.
DS Healthcare Group Files U.S. Patent on New Compound for Hair Loss
GlobeNewswire - Thu May 08, 7:00AM CDT
DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products, today announced it has filed its second patent with the U.S. Patent and Trademark Office. This new patent addresses the composition and methods of a new compound described as a calcium-activated potassium channel opening agent for topical treatment of hair loss. DS Healthcare had filed its first patent in October 2013 for its prescription hair loss product currently under development.
DS Healthcare Group to Roll Out Products in Sao Paulo the Largest City in Brazil's $46 Billion Beauty Market
GlobeNewswire - Thu Apr 10, 9:52AM CDT
DS Healthcare Group, Inc. (NASDAQ
SKX), a leading developer of personal care products, today announced it has signed a distribution agreement with Drogaria Iguatemi, the leading high-end retail drug store chain in Sao Paulo, Brazil. This marks the second major distribution agreement signed by DS Healthcare in Brazil's $43 billion beauty industry. The Company's products are experiencing robust sales growth in the Rio de Janeiro metropolitan area, as well as through DS Healthcare's Brazilian e-commerce site. DS Healthcare Group Reports 2013 Year-End and Fourth Quarter Financial Results
GlobeNewswire - Fri Apr 04, 7:17AM CDT
DS Healthcare Group, Inc. (Nasdaq
SKX), a leading developer of personal care products, today announced financial results for the three and twelve months ended December 31, 2013. DS Healthcare Group to Open its First Retail Boutique as Part of Global Brand Strategy
GlobeNewswire - Thu Feb 27, 8:52AM CST
DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products, today announced it is in the process of opening its first DS Laboratories retail store scheduled to open in the third quarter of 2014. The store, to be located in the metro Miami area, will showcase DS Healthcare's line of products including its industry-leading Spectral line of hair loss treatments and Revita hair stimulating shampoo and conditioner. The move is part of the Company's broader strategy as it continues to build the premier global brand in clinically proven personal care products.
DS Healthcare Group Signs Agreement with Leading Global Healthcare Company
GlobeNewswire - Mon Feb 10, 7:02AM CST
DS Healthcare Group, Inc. (NASDAQ
SKX), a leading developer of personal care products, today announced it has signed an agreement with a global healthcare company that ranks in the top 200 of the Fortune Global 500 list of largest corporations in the world in 2013. Per the terms of the agreement, DS Healthcare is providing the formulation, ingredients and its technology to the global healthcare company for use in a topical product. The product is to be launched and distributed by the global healthcare company under their own brand following successful development. Under the terms of the agreement, DS Healthcare will act as the exclusive ingredient supplier for a period of 5 years, which will automatically renew under certain conditions. DS Healthcare Group Moves Prescription Hair Loss Treatment Forward with Appointment of Aptiv Solutions as CRO
GlobeNewswire - Mon Jan 27, 7:00AM CST
DS Healthcare Group, Inc. (NASDAQ
SKX), a leading developer of personal care products, today announced it has appointed Aptiv Solutions as its clinical research organization (CRO) for its proprietary topical prescription treatment. If approved the drug will be positioned as frontline therapy in the fight against hair loss, a condition that affects nearly half of the population. DS Healthcare Group Prepares to File Investigational New Drug Application with FDA for Prescription Hair Loss Treatment
GlobeNewswire - Thu Jan 09, 7:00AM CST
DS Healthcare Group, Inc.(NASDAQ
SKX), a leading developer of personal care products, today announced it is preparing to submit to the United States Food and Drug Administration (FDA) an Investigational New Drug Application (IND) for its proprietary topical hair loss treatment. On October 29, 2013 the Company had announced it filed a patent with the United States Patent and Trademark Office for the invention. An IND is a request for the FDA's authorization to administer an investigational drug to humans and is the first step towards designing and conducting clinical trials in the U.S. DS Healthcare is currently in late stage discussions with various clinical research organizations (CROs) to design and conduct clinical trials for its breakthrough hair loss treatment. DS Healthcare Group Inc concludes USD3.144m private placement
M2 - Tue Jan 07, 7:55AM CST
Personal care products company DS Healthcare Group Inc (Nasdaq
SKX) announced on Monday the sale of 1,965,000 common shares for gross proceeds of USD3.144m to a group of accredited investors in a securities purchase agreement. DS Healthcare Group Completes Private Placement of $3,144,000 Dollars
GlobeNewswire - Mon Jan 06, 7:01AM CST
DS Healthcare Group, Inc. (Nasdaq: DSKX), a developer of personal care products, today announced that it has completed its securities purchase agreement with a group of accredited investors for the sale of 1,965,000 shares of the Company's common stock, with gross proceeds of $3,144,000. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS) acted as the placement agent in connection with the offering.
DS Healthcare Group Announces Private Placement of $2,420,000 Million Dollars
GlobeNewswire - Wed Dec 25, 10:00AM CST
DS Healthcare Group, Inc. (Nasdaq: DSKX), a developer of personal care products, today announced that it entered and consummated a securities purchase agreement with an accredited investor for the sale of 1,512,500 shares of the Company's common stock, with gross proceeds of $2,420,0000. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), acted as the placement agent in connection with the offering.
DS Healthcare Group announces planned availibility of oral tablet in hair-loss market
M2 - Thu Dec 05, 7:04AM CST
Personal care products company DS Healthcare Group Inc (NasdaqCM
SKX) stated on Wednesday that it will introduce its own proprietary over-the-counter neutraceutical tablet to combat premature hair thinning and improve healthy hair growth in the market. DS Healthcare Group to launch oral tablet in multi-billion-dollar hair-loss market
GlobeNewswire - Wed Dec 04, 8:56AM CST
DS Healthcare Group Inc.(NASDAQ
SKX), a leading developer of personal care products, announced that it has developed and will launch an over-the-counter neutraceutical tablet to combat premature hair thinning and improve healthy hair growth. Sold under the DS Laboratories brand, the tablet will complement and extend the company's industry-leading topical treatments, which promote longer, stronger, thicker hair. DS Healthcare Group Reports Third Quarter 2013 Results
GlobeNewswire - Fri Nov 15, 9:30AM CST
DS Healthcare Group, Inc.(NASDAQ
SKX), a leading developer of personal care products, today announced financial results for the three and nine months ended September 30, 2013. DS Healthcare Group, Inc. to Present at the Aegis Capital Corporation 2013 Healthcare Conference
GlobeNewswire - Thu Sep 19, 11:30AM CDT
DS Healthcare Group, NASDAQ (DSKX) announced today that Daniel Khesin, DS Healthcare's CEO, will present at the at the Aegis Capital Corporation 2013 Healthcare Conference on Saturday, September 28, 2013 at 11:00 AM PDT. The conference will be held at the Encore at Wynn Las Vegas on September 26-28, 2013.
DS Healthcare Group Launches Brazilian E-Commerce Site to Support Sales Momentum in Fast Growing Beauty Market
GlobeNewswire - Wed Sep 11, 12:00PM CDT
DS Healthcare Group, Inc. (NASDAQ
SKX), a leading developer of personal care products, today announced it has launched its Brazilian website: http://dslabshop.com.br. The e-commerce site provides convenient online shopping for Brazilians. The site also offers extensive product information to support in-stores sales of its products. OTC Daily Alert Stock Watch - DS Healthcare Group, Inc., (NASDAQ: DSKX)
WorldStockWire - Fri Aug 30, 12:30AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
DS Healthcare Group Inc's net loss widens to USD757,063 in Q2 2013
M2 - Wed Aug 21, 10:40AM CDT
Personal care company DS Healthcare Group Inc (NasdaqCM
SKX) stated on Tuesday its net loss of USD757,063 (USD0.06 per basic and diluted share) for the three months ended 30 June 2013. DS Healthcare Group Reports Second Quarter 2013 Results
GlobeNewswire - Tue Aug 20, 5:00AM CDT
DS Healthcare Group, Inc. (NASDAQ
SKX), a leading developer of personal care products, today announced results for the three and six months ended June 30, 2013. DS Healthcare Group Expands its Distribution Channels in $43 Billion Brazilian Beauty Market
GlobeNewswire - Mon Aug 05, 9:30AM CDT
DS Healthcare Group, Inc. (NASDAQ
SKX), a leading developer of personal care products, today announced it has expanded the distribution of its product lines into Brazil's CSB Drogaria which operates two retail pharmacy chains, Drogasmil and Farmalife, which together have 85 retail store locations. The stores are primarily located in the Rio de Janeiro metropolitan area. CSB Drogaria is owned by Profarma, a leader in the distribution to pharmacies, distributing 18 million units per month, through 31,000 sales outlets, covering 93% of the consumer market for pharmaceutical products in Brazil. Healthcare Group Inc updates results from new clinical trial of Spectral.DNC-S in the treatment of thinning hair
M2 - Thu Jul 18, 6:26AM CDT
Biotechnology company DS Healthcare Group Inc (NasdaqCM
SKX) Wednesday announced positive results from the clinical study of Spectral.DNC-S in the promotion of healthy hair and in the cessation of thinning hair in males. 
